## Carnegie "What-if" Explanations in an AI-Driven Clinical Decision-Mellon University Support Tool for Pulmonary Arterial Hypertension (PAH)





Katelyn Morrison<sup>1\*</sup>; Zexuan Li<sup>1\*</sup>; Shuyi Han<sup>2</sup>; Jidapa Kraisangka, PhD<sup>3</sup>; Charles Fauvel, MD<sup>4</sup>; Priscilla Correa-Jaque, MTDA<sup>5</sup>; Rebecca Vanderpool, PhD<sup>6</sup>; Yongqi Liu<sup>7</sup>; Shili Lin, PhD<sup>7</sup>; Adam Perer, PhD<sup>1</sup>; Allen Everett, MD<sup>8</sup>; Manreet Kanwar, MD<sup>9</sup>; Raymond Benza, MD<sup>5</sup>
1. Carnegie Mellon University, Pittsburgh, Pennsylvania, 2. University of California San Diego, San Diego, California, 3. Mahidol University, Nakhon Pathom, Thailand, 4. Cardiology Department, Rouen University Hospital, Rouen, France, 5. Icahn School of Medicine at Mount Sinai, New York, New York, 6. Division of Cardiovascular Medicine, The Ohio State University, Columbus, Ohio, 7. Department of Statistics, The Ohio State University, Columbus, Ohio, 8. The John Hopkins University, Baltimore, Maryland, 9. Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, Pennsylvania

# Background

- Clinicians **use risk stratification tools** to determine appropriate treatment plans for patients with PAH
- PAH risk stratification tools offer clinicians a calculated risk score with

### Results

- Identified why clinicians favor visualizing potential changes in risk related outcomes:
  - Educate patients, caregivers, and junior-level clinicians about PAH risk related survival
  - Actively engage patients in decision-making by demonstrating relevance of treatment changes

# little guidance on subsequent decision-making

- Clinicians think "what-if...?" and want to know how a particular intervention
  will affect a patient's risk and prognosis
- There is currently no way to visualize the potential change in risk until after prescribing treatment takes effect

### Goals

 Design interactive "what-if" scenarios to help guide clinicians through different patient outcomes by simulating potential changes in risk

- Navigate potential treatment plans
- Understand the risk stratification model
- Developed an interactive clinical decision-support tool for PAH risk assessment using the PHORA (Pulmonary Hypertension Outcome Risk Assessment)<sup>1</sup> model



- Help clinicians visualize potential patient outcomes of a decision before making that decision
- Identify how visualizing potential changes in risk can be useful to clinicians as they consider treatment changes

**Figure 1:** Designed interactive "what-if" scenarios feature to support clinicians' primary intended uses (<u>https://phora-user-study.web.app/</u>).

# **Conclusion & Implications**

**Clinicians find value in tools that help them visualize the potential outcomes** of treatment decisions. Such tools can aid in exploring treatment options, engaging patients in decision-making, and educating stakeholder about PAH.

We designed a tool that aims to support clinicians' essential



- Conducted semi-structured needfinding interviews and user studies with
  28 PAH clinicians
- Iteratively prototyped, progressing from static low-fidelity to interactive high-fidelity prototypes to a deployed, web-based interactive dashboard
- Thematic analysis of interview transcripts to inform dashboard design and clinician preferences
- **needs** and **educate patient**s when navigating PAH risk assessment and treatment planning.

### **References & Acknowledgements**

[1] Kanwar, M. K., Gomberg-Maitland, M., Hoeper, M., Pausch, C., Pittrow, D., Strange, G., ... & Benza, R. L. (2020). Risk stratification in pulmonary arterial hypertension using Bayesian analysis. European Respiratory Journal, 56(2).



www.myphora.org



National Institutes of Health

#### Project Number: R01HL164906